RA
TOVX icon

Royce & Associates’s Theriva Biologics TOVX Stock Holding History

Royce & Associates’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-32
Closed -$491K – 1384
2014
Q3 		$491K Hold
32
– – ﹤0.01% 1211
2014
Q2 		$475K Hold
32
– – ﹤0.01% 1231
2014
Q1 		$709K Sell
32
-57
-64% -$1.18M ﹤0.01% 1188
2013
Q4 		$1.19M Buy
89
+40
+82% +$505K ﹤0.01% 1148
2013
Q3 		$720K Hold
49
– – ﹤0.01% 1211
2013
Q2 		$737K Buy
+49
New +$670K ﹤0.01% 1191

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
RFC
Regions Financial Corp Birmingham, Alabama $15.4B AUM 21.7% 1-Year Est. Return

Royce & Associates's TOVX Position: Q4 2014 in Review

Royce & Associates sold out of Theriva Biologics (TOVX) in Q4 2014, closing a stake of 32 shares — an estimated $491K sold.

Royce & Associates first reported a position in TOVX in Q2 2013 and held it in 6 quarters. The position peaked at $1.19M in Q4 2013. 29 funds tracked by Wall St. Rank hold TOVX as of Q4 2014.

  • Royce & Associates reported no remaining Theriva Biologics position as of Q4 2014 after selling out during the quarter.
  • Royce & Associates sold 32 Theriva Biologics shares in Q4 2014, an estimated $491K.
  • Royce & Associates first reported a position in Theriva Biologics in Q2 2013 and held it in 6 quarters.
  • Royce & Associates's Theriva Biologics position peaked at $1.19M in Q4 2013.
  • 29 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2014.

Based on Royce & Associates's 13F filing for Q4 2014, filed 9 Feb 2015.